Disclosure regarding Rameda acquiring a selection of pharmaceutical products belong to diabetes and cholesterol treatment drugs Regulatory DisclosuresBy adminJune 1, 2023
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. finalizes acquisition of a portfolio of 11 fast-growing cardiometabolic products Corporate NewsBy adminJune 1, 2023